GlassScriptPhysician profile
Misty D Wheelock
NPI 1073700217
$9,216.79
in general payments reported to CMS, 2019-2025
58 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,715 · 2022: $2,401 · 2023: $1,401 · 2024: $1,136 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,101.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,320.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $846.35 | 2021-2024 | Relistor |
| Abbott Laboratories | $535.29 | 2021-2025 | Proclaim |
| Amgen INC. | $395.94 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $287.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $266.53 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $265.54 | 2021 | |
| Lilly USA, LLC | $255.78 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $253.89 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $246.54 | 2021-2024 | Xtampza, Belbuca |
| Takeda Pharmaceuticals U.S.A., INC. | $177.25 | 2021-2025 | Fruzaqla, Iclusig, Alunbrig |
| Janssen Biotech, INC. | $167.33 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $165.83 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $154.88 | 2024-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Glaxosmithkline, LLC. | $117.39 | 2024-2025 | Jemperli, Zejula, Ojjaara |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Wheelock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.